Hims & Hers Delivers Huge Growth Despite Stock Drop

Hims & Hers - our best performing pick ever - reported another outstanding quarter and fiscal year. For the year, revenues were up 69%, with Q4 coming in 95% higher than the comparable quarter last year - its fastest growth quarter of the year. The company has a lot of momentum. Monthly revenue per subscriber was up 19% of the year, 38% for the quarter. HIMS ended the year with 2.2 million subscribers, a 45% increase over last year. Yes, I know the stock has plummeted from $70 down to the low $40's, but the $70 number was just market foolishness over GLP hype. The truth is that less than 15% of Hims & Hers business is GLP drugs, and the company grew revenue 43% even taking that out entirely. With my new (and greatly raised) $35 price target, where it trades now is approaching fair value. This is going to be a wild ride, and my plan is to just ride it out. The trajectory should be up - way up - over time. Let your winners ride!

Watch List

CRWD 113.61%
NTNX 44.26%
VEEV 13.93%
SNOW 50.86%
WDAY -9.43%
ENLT -10.81%
WEAV -27.40%
SE 36.62%
SPSC 12.33%
RDDT 14.74%
APPF 13.92%
CMG 39.56%
INTU 44.44%
PSTG 12.28%

Buy List

TBBB -35.38%
SEMR -40.13%
ZETA -39.20%
GOOG -45.72%
ASR -29.43%
HRMY -55.45%
GLBE -28.96%
YOU -36.62%
MELI -29.05%
ADBE -39.09%

Hold List

PINS -14.33%
ASML -13.33%
VTEX 3.36%
TSM -24.34%
NYAX -24.98%
MSFT -13.80%
ODD 9.51%
FLYW -16.08%
CELH 32.77%
TOST 38.47%
CPNG 6.04%
HIMS 40.46%
PAYC -6.84%
MNDY 18.12%
ZS 81.90%
V -2.80%
ADSK 5.86%
NOW 19.40%
ABNB -23.85%
FTNT -0.17%
TEAM -15.16%